You searched for Health Technology Assessment (HTA) - Page 3 of 12 - OHE

We found for

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Read more

© WellcomeCollection

News
November 2021

Opportunity Cost in Health Care: a Favourite Research Topic for OHE

Insight
June 2021

Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?

Insight
April 2021

Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?

Insight
April 2021

Reconciling MCDA and Augmented Cost-Effectiveness Analysis: Do We Get the Same Decisions?

Insight
February 2021

‘HispaNICE’: the Creation of an ‘Independent Authority for the Evaluation of Health Practices and Policies’ Gathers Momentum

It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?

Read more

Payment Models for Multi-Indication Therapies

Read more

© Photology1971/Shutterstock

Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making

Read more

A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases

Read more

Insight
January 2021

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Cancer Treatments

How is Quality of Life Measured for Health Technology Assessments?

Read more

Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?

Read more

© Mitrovix

Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology

Read more

News
December 2020

Should We ‘Drop Dead’ from Health State Valuation?

Insight
December 2020

A NICE Wind of Change? The What and So What of the NICE Methods Consultation

01
02
03
04
05
06
07
00